Monday, October 28, 2024, at 8:30 a.m. EDT
DUBLIN and CHICAGO, Oct. 28, 2024 /PRNewswire/ --
WHO: |
|
WHAT: | Conference call to discuss U.S. Food and Drug Administration (FDA) approval of |
WHY: | ORLYNVAH (sulopenem etzadroxil and probenecid) is the first oral penem |
WHEN: | Monday, October 28, 2024 |
Dial-in information: | |
The conference call replay will be available in the Events & Presentations page of Iterum's website following the call. |
Iterum Therapeutics plc (Nasdaq: ITRM) is focused on deliveringAbout Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit .
SOURCE Iterum Therapeutics plc